Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2005 1
2006 2
2007 1
2013 2
2014 1
2015 1
2016 1
2017 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, Ikram A, Lanas F, Lourdes Guerrero M, Muñoz Navarro SR, Sued O, Lioznov DA, Dzutseva V, Parveen G, Zhu F, Leppan L, Langley JM, Barreto L, Gou J, Zhu T; CanSino COVID-19 Global Efficacy Study Group. Halperin SA, et al. Among authors: barreto l. Lancet. 2022 Jan 15;399(10321):237-248. doi: 10.1016/S0140-6736(21)02753-7. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953526 Free PMC article. Clinical Trial.
Polio vaccine: the first 50 years and beyond.
Griffiths E, Wood D, Barreto L. Griffiths E, et al. Among authors: barreto l. Biologicals. 2006 Jun;34(2):73-4. doi: 10.1016/j.biologicals.2006.03.007. Epub 2006 May 5. Biologicals. 2006. PMID: 16678441 No abstract available.
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia.
Lioznov D, Amosova I, Sheetikov SA, Zornikova KV, Serdyuk Y, Efimov GA, Tsyferov M, Khmelevskii M, Afanasiev A, Khomyakova N, Zubkov D, Tikhonov A, Zhu T, Barreto L, Dzutseva V. Lioznov D, et al. Among authors: barreto l. PLoS One. 2023 Mar 8;18(3):e0278878. doi: 10.1371/journal.pone.0278878. eCollection 2023. PLoS One. 2023. PMID: 36888640 Free PMC article. Clinical Trial.
Conquering the crippler: Canada and the eradication of polio.
Rutty CJ, Barreto L, Van Exan R, Gilchrist S. Rutty CJ, et al. Among authors: barreto l. Can J Public Health. 2005 Mar-Apr;96(2):I2-24. Can J Public Health. 2005. PMID: 15850030 English, French. No abstract available.
Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age.
Gold R, Barreto L, Ferro S, Thippawong J, Guasparini R, Meekison W, Russell M, Mills E, Harrison D, Lavigne P. Gold R, et al. Among authors: barreto l. Can J Infect Dis Med Microbiol. 2007 Jul;18(4):241-8. doi: 10.1155/2007/289842. Can J Infect Dis Med Microbiol. 2007. PMID: 18923741 Free PMC article.
13 results